The US FDA has approved filgrastim-laha, a leukocyte growth factor biosimilar for the treatment of neutropenia, neutropenia associated with chemotherapy, neutropenia associated with radiation, bone marrow transplantation, and peripheral progenitor cell transplantation. Filgrastim-laha is indicated to: Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy…